Endocrine Abstracts

Background and Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common comorbidity of obesity. In this study, we sought to determine hepatic metabolic and mitochondrial effects of the Glucagon-like Peptide-1-agonist semaglutide, the sodium-glucose linked transporter 2-inhibitor empagliflozin and Peptide YY3-36 in diet-induced obese rats with additional chronic inhibition of nitric oxide synthase via Nω-nitro-L-arginine meth...

Introduction: The prevalence of obesity, a chronic disease with significant morbidity, has rapidly increased in recent decades. Semaglutide, an injectable glucagon-like peptide-1 agonist, has gained global popularity after its approval for weight management in 2021. All studies have reported marked variability in semaglutide response, with a small proportion of patients (10-16%) showing inadequate response. Data about the predictors of poor response to semaglutide for weight l...

The pathological expansion of white adipose tissue (WAT) in obesity involves adipocyte hypertrophy accompanied by expansion of collagen-rich pericellular extracellular matrix (ECM) and the development of crown-like structures (CLS). Traditionally, WAT morphology is assessed through immunohistochemical analysis of WAT sections. However, manual analysis of large histological sections is time-consuming, and available digital tools for analyzing adipocyte size and pericellular ECM...

Aims: To investigate differences in maternal and foetal outcomes in pregnancy, where patients developed hypoglycaemia following the 2-hour 75 g oral glucose tolerance test (OGTT).Method: A retrospective cohort study of 200 pregnancies attending the Antenatal Clinic at Tameside General Hospital between 2018 and 2022. Outcomes were compared between 4 groups: normal OGTT [G1; (n=39, 20%], hyperglycaemia following OGTT [G2; BG ≥5.6 mmol/litre ...

Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently accompanies obesity, posing a significant health concern. The Neuropeptide Y (NPY) system, a key player in energy metabolism regulation, has implications for liver health, yet the impact of NPY receptor antagonists remains largely unexplored. This study investigates the effects of antagonists targeting the NPY-2 receptor (Y2R) in comparison to known MASLD-beneficial substances.Me...